GLP-1 / Weight Loss

Semaglutide

Also known as: Ozempic · Wegovy · Rybelsus

The gold standard GLP-1 agonist for weight loss and metabolic health.

Half-Life
~7 days (designed for once-weekly dosing)
Administration
Subcutaneous injection (weekly)
Category
GLP-1 / Weight Loss
Citations
2 studies

What is Semaglutide?

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the gut hormone GLP-1 to suppress appetite, slow gastric emptying, and improve insulin sensitivity. Originally developed for type 2 diabetes (Ozempic), it became a blockbuster weight loss drug (Wegovy) after clinical trials showed 15% average body weight reduction.

Mechanism of Action

Semaglutide binds to GLP-1 receptors in the brain (hypothalamus), gut, and pancreas. It suppresses appetite by reducing ghrelin and increasing satiety signals, slows gastric emptying to reduce caloric intake, stimulates insulin secretion in a glucose-dependent manner, and reduces glucagon secretion. It also has direct cardiovascular protective effects.

Semaglutide Dosing Protocol

Start at 0.25 mg/week subcutaneous for 4 weeks → 0.5 mg/week for 4 weeks → 1 mg/week → titrate to 2.4 mg/week (max for weight loss). For diabetes: 0.5–1 mg/week. Inject once weekly, same day each week.

Administration Routes
Subcutaneous injection (weekly)
Half-Life
~7 days (designed for once-weekly dosing)

Want a personalized protocol? Tell PepBot your goals, health status, and experience level for a custom Semaglutide protocol.

Semaglutide Benefits

15% average body weight reduction in clinical trials
Improved insulin sensitivity
Reduced cardiovascular risk (SUSTAIN-6 trial)
Appetite suppression
Blood sugar regulation
Potential neuroprotective effects
Reduced liver fat

Side Effect Profile

Nausea (most common, especially during titration), vomiting, diarrhea, constipation. Rare: pancreatitis, gallbladder issues. Titrate slowly to minimize GI side effects. Not for use with personal/family history of medullary thyroid carcinoma.

Semaglutide Stacking Guide

Semaglutide works synergistically with these compounds. Click any to learn more, or ask PepBot to build you a complete stack.

Research & Citations

Frequently Asked Questions about Semaglutide

How much weight can I lose on Semaglutide?
In the STEP 1 clinical trial, participants lost an average of 14.9% of body weight over 68 weeks at 2.4 mg/week. Some individuals lose 20%+. Results are significantly better when combined with a caloric deficit and resistance training.
What is the difference between Semaglutide and Tirzepatide?
Semaglutide is a GLP-1 agonist only. Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist and shows superior weight loss (~22.5% vs ~15%). If weight loss is the primary goal, Tirzepatide wins. Semaglutide has more long-term cardiovascular data.

Still have questions about Semaglutide?

PepBot has encyclopedic knowledge of Semaglutide — dosing, stacking, interactions, latest research, and personalized protocols. Ask anything.